1. Clinical & Scientific Overview
Dutasteride (Dual Type-1/Type-2 5-Alpha-Reductase Inhibitor) (TIP-MED-000241, Reference Code [12.9]) is classified under
Urological & Renal Stone Medicines (Ch 12) as a Dual Type-1 and Type-2 5-Alpha-Reductase Inhibitor.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.9], p. 159): Duprost, Veltride, Dutas (FDC with Tamsulosin: Urimax-D, Veltam-Plus) — Strengths & Dosage Forms: Soft Gelatin Capsule / Tablet: 0.5 mg.
Soft Gelatin Capsule / Tablet: 0.5 mg.
3. Mechanism of Action & Pharmacodynamics
Inhibits both Type-1 and Type-2 isoenzymes of 5-alpha-reductase -> blocks conversion of testosterone to dihydrotestosterone (DHT), reducing serum DHT by >90%.
4. Therapeutic Indications & Evidence-Supported Uses
- Moderate-to-severe benign prostatic hyperplasia (reduces prostate volume by ~25-30% and prevents acute urinary retention/BPH surgery)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: 0.5 mg PO once daily (requires 3-6 months of continuous therapy for maximal prostate shrinkage). • Paediatric: Contraindicated in children and adolescents.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: No dose adjustment required in renal impairment (<0.1% excreted unchanged in urine). • Hepatic: Metabolised extensively by CYP3A4/3A5; caution in mild-to-moderate liver disease; avoid in severe hepatic impairment.
Renal: No dose adjustment required in renal impairment (<0.1% excreted unchanged in urine). • Hepatic: Metabolised extensively by CYP3A4/3A5; caution in mild-to-moderate liver disease; avoid in severe hepatic impairment.
Renal: No dose adjustment required in renal impairment (<0.1% excreted unchanged in urine). • Hepatic: Metabolised extensively by CYP3A4/3A5; caution in mild-to-moderate liver disease; avoid in severe hepatic impairment.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Women, children, and adolescents; pregnancy (Category X teratogen). • Precautions: TERATOGENIC HAZARD: Absorbed percutaneously through skin—women who are pregnant or may become pregnant must NEVER handle crushed, leaking, or broken capsules (causes feminisation of male fetus). Reduces serum PSA by ~50% after 6 months (multiply measured PSA by 2 when screening for prostate cancer).
Key Clinical Precautions: Renal: No dose adjustment required in renal impairment (<0.1% excreted unchanged in urine). • Hepatic: Metabolised extensively by CYP3A4/3A5; caution in mild-to-moderate liver disease; avoid in severe hepatic impairment.
8. Adverse Effects Profile
- Erectile dysfunction, decreased libido, ejaculatory disorders, gynaecomastia/breast tenderness.
- High-grade prostate cancer masking if PSA doubling rule is ignored, depressive mood, angioedema.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CYP3A4 inhibitors (Verapamil, Diltiazem, Itraconazole, Ritonavir) -> decrease dutasteride clearance
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Swallow capsule whole; pregnant women must never touch leaking capsules; takes 3-6 months to shrink the prostate; tell your doctor you take Dutasteride before any PSA blood test; do not donate blood during treatment and for 6 months after stopping.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM | Compendia: IP 2026 / NFI 7th Ed 2026 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Soft Gelatin Capsule / Tablet: 0.5 mg.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.9] (p. 159)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.2] Finasteride (and Dutasteride comparison) — 5-Alpha-Reductase Inhibitor (5-ARI; Blocks Intracellular Conversi
- [12.3] Solifenacin Succinate — Urinary Bladder-Selective Muscarinic M3-Receptor Antagonist (Anti
- [12.4] Mirabegron — Selective Beta-3 Adrenoceptor Agonist (Relaxes Detrusor Smooth Mu
- [12.8] Silodosin (Uroselective Alpha-1A Blocker for BPH) — Highly Uroselective Alpha-1A Adrenergic Receptor Antagonist